Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 12Nivolumab 6Cyclophosphamide 6fludarabine 5Ipilimumab 4amatuximab 3Cisplatin 3tislelizumab 2spartalizumab 2fludarabine phosphate 2budigalimab 2belinostat 2Plicamycin 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorouracil 2Cytoreduction Surgical Procedures 2venetoclax 1tocilizumab 1talazoparib 1sotorasib 1rovalpituzumab tesirine 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1irinotecan sucrosofate 1epacadostat 1enzalutamide 1durvalumab 1defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × OSI 930 × Gastrointestinal × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡